PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565674
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565674
Pre-Exposure Prophylaxis (PrEP) Market size was valued at USD 4,980.43 Million in 2023, expanding at a CAGR of 12.30% from 2024 to 2032.
Pre-exposure prophylaxis (PrEP) is a preventive treatment for high-risk individuals to reduce HIV infection. It involves taking a daily pill containing antiretroviral drugs. The PrEP market includes developing, manufacturing, and distributing these medications. This market has expanded due to increased HIV prevention awareness and access. Key players include pharmaceutical companies and healthcare providers. Ongoing research aims to improve PrEP options and explore new formulations.
Pre-Exposure Prophylaxis (PrEP) Market- Market Dynamics
Increased awareness and education about PrEP's effectiveness and availability.
Increased awareness and education about PrEP's effectiveness and availability significantly drive the PrEP market. As more people understand how PrEP can prevent HIV, demand for the drug rises. the Centers for Disease Control and Prevention (CDC) reported that increased awareness campaigns led to a substantial rise in PrEP use among high-risk populations.
The U.S. Centers for Disease Control and Prevention (CDC) reported that as of 2021, nearly 60% of individuals at high risk of HIV were aware of PrEP. The CDC also noted a 25% increase in PrEP prescriptions from 2018 to 2021, reflecting this preventive treatment's growing awareness and adoption. This rise in awareness and utilization is a key driver for the expanding PrEP market.
Pre-Exposure Prophylaxis (PrEP) Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.30% over the forecast period (2024-2032)
Based on product type segmentation, branded PrEP was predicted to show maximum market share in the year 2023
Based on Usage Type segmentation, daily oral PrEP was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Pre-Exposure Prophylaxis (PrEP) Market is segmented on the basis of Product Type, Usage Type, End User, and Region.
The market is divided into two categories based on product type Generic PrEP, Branded PrEP. In the Pre-Exposure Prophylaxis (PrEP) market, the branded PrEP segment is currently the most dominant. This is largely due to the strong market presence and extensive promotion of branded products like Truvada and Descovy. Branded PrEPs benefit from established brand recognition, comprehensive clinical support, and extensive distribution networks. They also often receive preferential recommendations from healthcare providers due to their proven efficacy and safety profiles. In contrast, generic PrEPs, while increasing in availability, still face challenges in gaining market share due to lower brand recognition and potentially less comprehensive support.
The market is divided into two categories based on the Usage Type Daily Oral PrEP. Long-Acting Injectables In the Pre-Exposure Prophylaxis (PrEP) market, the daily oral PrEP segment is currently the most dominant. This dominance stems from the long-standing use and clinical validation of daily oral PrEP, such as Truvada and Descovy, which have a well-established track record for efficacy and safety. Daily oral PrEP is widely available and accepted by healthcare providers, contributing to its significant market share. Long-acting injectables are emerging but have not yet achieved the same level of market penetration due to newer market entry and fewer long-term data points.
Pre-Exposure Prophylaxis (PrEP) Market- Geographical Insights
The largest region for the Pre-Exposure Prophylaxis (PrEP) market is North America, particularly the United States. This region leads due to its advanced healthcare infrastructure, high awareness of HIV prevention, and strong support from public health initiatives. The U.S. also benefits from significant investments in research and development for PrEP medications. The availability of PrEP through various healthcare programs and insurance coverage further boosts its adoption. North America's market dominance is supported by robust regulatory frameworks and active advocacy groups promoting PrEP usage.
The Pre-Exposure Prophylaxis (PrEP) market is highly competitive, with several major players dominating the landscape. Gilead Sciences, Inc.leads with its PrEP product, Truvada, and its newer formulation, Descovy. ViiV Healthcare follows with Apretude, a long-acting injectable PrEP option. Bristol-Myers Squibb and Janssen Pharmaceuticals are also significant, with ongoing research and potential PrEP developments. Merck & Co., Inc. and AbbVie Inc. contribute through their HIV research and emerging PrEP solutions. Roche and Pfizer Inc. are involved in HIV treatments, influencing the PrEP market. Sage Therapeutics and Moderna, Inc. are innovative players exploring new prevention methods. Mylan N.V., Hikma Pharmaceuticals, Cipla Limited, and Aurobindo Pharma provide generic PrEP options, expanding access and affordability. This competitive landscape is characterized by continuous innovation and development aimed at improving prevention and treatment outcomes for HIV.
In September 2024, with yet another phase 3 victory, Gilead is racing to introduce a long-acting PrEP medication in 2025.
In April 2023, Merck & Co. (MRK.N) said that it will acquire Prometheus Biosciences Inc. (RXDX.O) for approximately $10.8 billion. The acquisition will allow Merck to expand its foothold in immunology and acquire a potential experimental treatment for ulcerative colitis and Crohn's disease.